Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell L...(looking at the problem in the hope of fi...),Health

Date:5/28/2008

looking at the problem, in the hope of finding a better solution. That's why this study is so important. It has opened a door that points to histology as a way of helping physicians decide which lung cancer treatment may work best for a particular patient," said Richard Gaynor, M.D., vice president of cancer research and global oncology platform leader at Lilly.

Notes to Editor

About Non-Small Cell Lung Cancer (NSCLC)

NSCLC is the most common type of lung cancer and represents 85 to 90 percent of all lung cancers.(1) NSCLC has five-tier staging, starting at 0 and rising to the severity of stage IV.(2) NSCLC can spread through the lymphatic system, penetrating the chest lining, ribs, and the nerves and blood vessels that lead to the arm. The liver, bones and brain are potential targets if the cancerous cells enter the bloodstream.

According to the World Health Organization (WHO) Cancer Report, lung cancer is the world's most common cancer and the leading cause of cancer death for both men and women. More than 1 million people die from lung cancer each year.(3)

NSCLC is defined as a group of histologies, that is, tumor types differentiated by cellular structure. The most common NSCLC histology types are squamous (or epidermoid) carcinoma, adenocarcinoma, and large cell carcinoma. These histologies are often classified together because, to date, approaches to diagnosis, staging, prognosis, and treatment have been similar.(4)

About Lilly Oncology, a Division of Eli Lilly and Company

For more than four decades, Lilly Oncology has been collaborating with cancer researchers to deliver innovative treatment choices and valuable programs to patients and their physicians. Inspired by courageous patients living with cancer, Lilly Oncology is providing treatments that are considered global standards of care and developing a broad portfolio of novel targeted therapies to accelerate the pace and progress of cancer care. To learn mo
'/>"/>

SOURCE Eli Lilly and Company Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine news :

1. Global study reveals differences in standard of care for osteoporosis across the world
2. New study shows positive role physical therapists play in lymphedema diagnois and treatment
3. RTOG Study Likely Treatment Option for Brain Tumor Patients like Sen. Kennedy
4. New CDC Study Shows Smoke-Free Laws Spreading Across U.S. and Should Spur Remaining States to Take Action
5. Experimental agent blocks prostate cancer in animal study
6. Study finds unique HIV vaccine formula elicits strong immune responses
7. First of its kind study compares high school knee injuries by sport and gender
8. UNC study firms up promise of potential new cervical cancer screening tool
9. Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50
10. Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon
11. Israeli study finds obstructive sleep apnea is health factor from day 1